Turning Point Therapeutics

• NCT05828303

  Phase 1, Withdrawn, 0 people, 25 Apr 2023

• NCT05071183

  Phase 1/2, Terminated, 9 people, 8 Oct 2021

• Type 1 interferon perturbates clonal competition by reshaping human blood development

  Grants or research support, 15 Sept 2026

Sources: pubmed.ncbi.nlm.nih.gov